Back to top

Analyst Blog

Mylan Inc. (MYL - Analyst Report) recently announced that the US district court for the southern district of N.Y. has issued a favorable final judgment in a patent infringement case with Sunovion Pharmaceuticals.

The final verdict was in line with the decision issued by the Court of Appeals for the Federal Circuit. According to the order issued by the court, Mylan’s five patents related to its chronic obstructive pulmonary disease drug Perforomist stand as valid and enforceable and are infringed by Sunovion’s Brovana. Brovana is approved for controlling the symptoms of COPD, including chronic bronchitis and emphysema. Both Brovana and Perforomist are long-acting beta-2 agonists.

In 2012, Mylan settled its patent dispute with Sunovion Pharma pertaining to Brovana. Sunovion recognized that Brovana infringed two of Mylan’s patents, which are valid till Jun 22, 2021.

Following the currently issued favorable ruling, Mylan’s seven patents pertaining to Perforomist stand as valid and enforceable and are infringed by Sunovion’s Brovana.

We note that the Perforomist inhalation solution is marketed by the Mylan Specialty segment. The drug performed well in the first quarter of 2013. The most significant product in this segment is EpiPen auto-injector, which is used to treat severe allergic reactions.

The bulk of the revenues come from the company's generic division. The  generics business has been consistently performing well. Mylan’s generic unit has seen quite a few launches over the past few months. One of the important recent launches includes the company's generic version of Pfizer Inc.’s (PFE - Analyst Report) erectile dysfunction drug Viagra. Dr. Reddy's Laboratories Ltd. (RDY - Analyst Report) too has been making multiple generic launches over the past few months.

Mylan carries a Zacks Rank #2 (Buy). Simcere Pharmaceutical Group appears to be equally attractive.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%